Does Wegovy Ever Not Work — and What Can You Do About It?

The biggest misconception: if Wegovy isn't working, you must be doing something wrong

The most persistent myth is that semaglutide always works, so any shortfall is the patient's fault, too many calories, not enough effort, not following instructions. The trials tell a different story. In the STEP 1 trial published in the New England Journal of Medicine, semaglutide 2.4mg produced around 15% average body-weight reduction at 68 weeks alongside lifestyle changes. Average. Some participants lost 25% or more. Others lost under 5%. Biology is real, and appetite-regulation pathways differ from person to person.

The GLP-1 receptor that semaglutide targets varies in expression and sensitivity between individuals. Gut motility, baseline insulin secretion, genetic factors affecting satiety signalling, none of these are visible when you place an order. They only become clear as treatment progresses. This is precisely why clinical review matters at every stage, not just at the point of prescription. If you want a fuller picture of how Wegovy works at a biological level, that detail matters when assessing why a response might be blunted.

The corrected picture: Wegovy works for most people, meaningfully so. For a minority it delivers little benefit. That minority deserves honest answers and a clinical conversation, not reassurance that they must be doing something wrong.

The reasons Wegovy can fall short, and which are fixable

There is a meaningful difference between Wegovy genuinely not working and Wegovy not being given a proper chance to work. Several common patterns look like non-response but have a practical cause.

Under-titration is the most frequent one. The starting dose of 0.25mg exists to let your system adjust, it is not expected to produce weight loss on its own. Some patients, particularly those who experience nausea, stay on lower doses longer than the schedule recommends and never reach 2.4mg maintenance. If you are curious about the full clinical profile of semaglutide, including how dose progression works, that page covers it. A quick self-check you can do in under a minute: look at your dispensing history and note which pen strength you are actually on. If you have been on 0.5mg or 1mg for more than three months and losing nothing, the dose itself may be the conversation to have with your prescriber.

Other fixable factors include: medicines that counteract appetite suppression (certain antidepressants, corticosteroids, antipsychotics); untreated hypothyroidism; or sleep apnoea that is disrupting metabolic signalling. None of these make semaglutide useless, but they all reduce its headroom. There is also the question of genuine GI intolerance, persistent nausea or vomiting that prevents reaching a therapeutic dose. That is not a failure of will; it is a pharmacological signal that needs clinical management. Some people are simply less likely to respond, and identifying that pattern early is the point of structured follow-up.

When the evidence says it is time to change course

NICE's appraisal of semaglutide for weight management (TA875) recommends that clinicians consider stopping treatment if a patient loses less than 5% of their body weight after six months at the full maintenance dose. That threshold is not arbitrary, it reflects the point at which the expected benefit no longer justifies continued prescription. It also matters for cost; the cost of Wegovy over several months is significant, so staying on a treatment that is not producing results serves no one.

What TA875 also makes clear is that continuation should be reviewed within a structured programme. This is where private provision differs from self-managed treatment: a service with no clinical follow-up gives you a product; a service with genuine aftercare gives you a clinical relationship that catches non-response early. At our pharmacy, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed. That review is the mechanism by which poor response gets surfaced and addressed, not buried.

If you have been losing very little despite reaching maintenance dose, the answer is not always to persist. It might be switching to a different treatment, investigating an underlying cause, or pausing to reassess. Switching to tirzepatide (Mounjaro) is a recognised clinical option; the SURMOUNT-5 trial demonstrated greater average weight loss with tirzepatide than with semaglutide 2.4mg, though what suits a particular person is always a clinical decision.

Wegovy not working versus Wegovy working differently than expected

A separate conversation is the one about expectations. Some people lose weight at a rate they find disappointing (say, 6 or 8% over six months) and interpret that as the medicine not working. By the measure NICE uses, 6% is a response. By the measure of a trial average of 15%, it feels like falling short. Both things are true simultaneously.

It is also worth knowing that Wegovy's effect on individuals is not linear. Weeks three to eight are often the hardest: appetite suppression is building, GI effects peak, and the scale may barely move. People who stop during this window sometimes conclude the medicine failed, when it had not yet had the chance to work. Conversely, some unexpected effects (changes in energy, mood, or other aspects of wellbeing) can appear alongside or instead of the weight loss someone was hoping for, and those deserve clinical attention too.

The honest answer to the original question is this: yes, Wegovy sometimes does not work, and that is a medically recognised fact. What varies is why, and whether anything can be done about it. That answer comes from a clinician, not a forum. If you want to explore whether semaglutide is right for you, or to discuss a response that has not met your expectations, you can start a free consultation with our prescribers.